{"id":837914,"date":"2025-04-16T07:34:40","date_gmt":"2025-04-16T11:34:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/"},"modified":"2025-04-16T07:34:40","modified_gmt":"2025-04-16T11:34:40","slug":"briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/","title":{"rendered":"BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Median overall survival of 17.3 months in Bria-IMT\u2122 treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY<sup>\u00ae<\/sup> (sacituzumab govitecan-hziy) in similar heavily pre-treated patients<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Survival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY<sup>\u00ae <\/sup><\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>No Bria-IMT related discontinuations reported to date<\/em><br \/>\n          <\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, April  16, 2025  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors (CPI), outperforming ADC drugs in hormone receptor positive (HR+) metastatic breast cancer (MBC) patients.<\/p>\n<p align=\"justify\">In BriaCell\u2019s Phase 2 clinical study in late-stage MBC, 25 of 37 patients treated with the ongoing pivotal Phase 3 Bria-IMT formulation were identified as having HR+ breast cancer. As shown in Table 1, the survival data of these 25 patients (17.3 months) exceeds those of the current ADC standard of care TRODELVY<sup>\u00ae<\/sup> (14.4 months). The survival data for the Bria-IMT regimen + immune check point inhibitor in the triple negative breast cancer (TNBC), characterized by the absence of estrogen (ER), progesterone (PR) and human epidermal growth factor (HER2) receptors, was similar to TRODELVY<sup>\u00ae<\/sup> but still markedly higher (70%) than those of chemotherapy.<\/p>\n<p align=\"justify\">\u201cWe are truly impressed with the survival benefit data of the regimen that exceeds or meets those of TRODELVY<sup>\u00ae<\/sup> in HR+ and TNBC metastatic breast cancer patients, respectively. Bria-IMT appears to be very well-tolerated,\u201d stated Dr. William V. Williams, BriaCell\u2019s President and CEO. \u201cWe look forward to further confirming this clinical data in our ongoing pivotal Phase 3 study with overall survival as its primary endpoint.\u201d<\/p>\n<p align=\"justify\">\u201cHR+ and TNBC metastatic breast cancer represent a significant proportion of the patient population and are the most difficult patient groups to treat. They have limited therapeutic options and overall survival of only a few months,\u201d commented Dr. Giuseppe Del Priore, BriaCell\u2019s Chief Medical Officer. \u201cOur clinical data supports our hypothesis that the Bria-IMT regimen + CPI has the potential to address the unmet medical needs of HR+ and TNBC MBC patients and provide an effective and well-tolerated therapeutic option.\u201d<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"4\" style=\"vertical-align: middle\">\n            <strong>Table 1: Comparable Analysis of median overall survival (estimated using the Kaplan-Meier method) for the BriaCell Phase 2 study of BriaCell\u2019s Bria-IMT\u2122 plus CPI versus other drugs in MBC patient subsets<br \/><\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:25%;width:25%;min-width:25%;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"max-width:25%;width:25%;min-width:25%;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"max-width:25%;width:25%;min-width:25%;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"max-width:25%;width:25%;min-width:25%;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle\">\n            <strong>Reference<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle\">\n            <strong>Breast Cancer <br \/>Type<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>Median # of prior<br \/> lines of therapy<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;border-right: solid black 1pt;vertical-align: middle\">\n            <strong>Median OS<br \/> (months)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: double black 3pt;border-left: double black 3pt;border-right: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 15.0px;border-bottom: double black 3pt;vertical-align: middle\">\n            <strong>Bria-IMT plus CPI*<\/strong>\n          <\/td>\n<td style=\"border-top: double black 3pt;border-right: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 15.0px;border-bottom: double black 3pt;vertical-align: middle\">\n            <strong>HR+<\/strong>\n          <\/td>\n<td style=\"border-top: double black 3pt;border-right: solid black 1pt;text-align: center;vertical-align: middle;border-bottom: double black 3pt;vertical-align: middle\">\n            <strong>6<\/strong>\n          <\/td>\n<td style=\"border-top: double black 3pt;border-right: double black 3pt;text-align: center;vertical-align: middle;border-bottom: double black 3pt;vertical-align: middle\">\n            <strong>17.3<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" style=\"border-left: double black 3pt;border-right: solid black 1pt;border-bottom: double black 3pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>TRODELVY<sup>\u00ae<\/sup><sup>1<\/sup><br \/>(sacituzumab govitecan-hziy)<br \/><\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 15.0px;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>HR+<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>4<\/strong>\n          <\/td>\n<td style=\"border-right: double black 3pt;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>14.4<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: double black 3pt;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle\">\n            <strong>Single agent<br \/> chemotherapy<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: double black 3pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>4<\/strong>\n          <\/td>\n<td style=\"border-right: double black 3pt;border-bottom: double black 3pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>11.3<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: double black 3pt;border-right: solid black 1pt;border-left: double black 3pt;vertical-align: middle;text-align: left;padding-left: 15.0px;border-bottom: double black 3pt;vertical-align: middle\">\n            <strong>Bria-IMT plus CPI*<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-top: double black 3pt;vertical-align: middle;text-align: left;padding-left: 15.0px;border-bottom: double black 3pt;vertical-align: middle\">\n            <strong>TNBC<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-top: double black 3pt;text-align: center;vertical-align: middle;border-bottom: double black 3pt;vertical-align: middle\">\n            <strong>6<\/strong>\n          <\/td>\n<td style=\"border-top: double black 3pt;border-right: double black 3pt;text-align: center;vertical-align: middle;border-bottom: double black 3pt;vertical-align: middle\">\n            <strong>11.4<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" style=\"border-right: solid black 1pt;border-left: double black 3pt;border-bottom: double black 3pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>TRODELVY<sup>\u00ae<\/sup><sup>1<\/sup><br \/>(sacituzumab govitecan-hziy)<br \/><\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 15.0px;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>TNBC<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>3**<\/strong>\n          <\/td>\n<td style=\"border-right: double black 3pt;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>11.8<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: double black 3pt;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle\">\n            <strong>Single agent <br \/>chemotherapy<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: double black 3pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>3**<\/strong>\n          <\/td>\n<td style=\"border-right: double black 3pt;border-bottom: double black 3pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>6.9<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"4\" style=\"vertical-align: middle\">* Patients treated with the Phase 3 formulation<br \/>** Number of prior chemotherapy-containing regimens<\/td>\n<\/tr>\n<tr>\n<td colspan=\"4\" style=\"vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"4\" style=\"text-align: left;vertical-align: middle;vertical-align: middle\"> 1.\u00a0<a href=\"https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/trodelvy\/trodelvy_pi.pdf\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/trodelvy\/trodelvy_pi.pdf<\/a><\/td>\n<\/tr>\n<tr>\n<td colspan=\"4\" style=\"vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Abbreviations: <\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>HR+:<\/em><br \/>\n        <\/strong><br \/>\n        <em> hormone receptor-positive<\/em><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>TNBC:<\/em><br \/>\n        <\/strong><br \/>\n        <em> Triple-negative breast cancer (lacks the estrogen receptor, progesterone receptor, and lacks or has low levels of human epidermal growth factor receptor 2 (HER2))<\/em>\n      <\/p>\n<p align=\"justify\">The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients (median number of prior treatments = 6) who received the Bria-IMT regimen plus checkpoint inhibitor. Of these 54 patients, 37 were treated with the formulation currently being used in BriaCell\u2019s ongoing pivotal Phase 3 study in metastatic breast cancer (listed on ClinicalTrials.gov as\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EcRl8QwAoybEbgsivCYTa1kRVE-54V4RAxKbu_cojc4FAHepzhuJiBXy6G2yb_GGDeOaWSvqcDoy9LToAjMcYp9WzkbEe-UncaGJDCFy-9t7vF80Am749NnimM3O7y0_\" rel=\"nofollow\" target=\"_blank\">NCT06072612<\/a>). No Bria-IMT related discontinuations have been reported to date.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TTH-3RFRMd4od5VWYCtPTwSqAH2PXKKoqnt5CNUAPkT8zYvyue7jT8nv2mcJwyFOFdr-3589aQlTnmKi8xnxvrV4tNaUz6A6q3ThaO0_nFM=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including statements about: BriaCell further confirming positive clinical data in its ongoing pivotal Phase 3 study; BriaCell\u2019s further clinical development of Bria-IMT\u2122; the Company\u2019s beliefs regarding the results of BriaCell\u2019s pivotal Phase 3 study; and the Company\u2019s beliefs that the Bria-IMT\u2122 regimen + CPI has the potential to address the unmet medical needs of HR+ and TNBC MBC patients and provide an effective and well-tolerated therapeutic option, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company\u2019s profiles on SEDAR+ at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VMjZcmnZtL5BxMYzuVZTGGIuapsWkK4x6YU4-g8zDH6VeiJVpUzm6xwMLXvuW44fOJl9iNk4kpZsALnwXHJp7sU1BAD_oZJohgTtD6b8wOYGieG3-k2dRI7PFhhhFC-g\" rel=\"nofollow\" target=\"_blank\"><strong>www.<\/strong><strong>sedarplus<\/strong><strong>.ca<\/strong><\/a> and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VMjZcmnZtL5BxMYzuVZTGBMth6vHuujOzggAWjqAkPXaCXu73jh4hdBvB0I-KcvDSsrgbp0zNpa2YXNrRg44CQ==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xXo6g21entTujSVQLU0wuPCwtr7jxpF_paH-3KS2pBXWQiOITIe4iSyeR3SZUulxZIE_sanm7KYawM70sDZ2Dur9mtYXTV1uFFRNlUWhe1c=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y1PfIwqmSl3ea2Ztw1RQUsABs2XK6ym2j9MtcKbkYbd0DmgUwrWO_NQ5OhT_h3yJBGm2WdHvw8DDiLjwQxqvhaU8LR-I7IftdLIj9R5asZ4=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzIzNSM2ODY4ODU3IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Yzk4NDNjMTMtMTg0Zi00ODZmLThiNDgtZjllYmI1ZWQ1Y2NlLTExMDIyMjktMjAyNS0wNC0xNi1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Median overall survival of 17.3 months in Bria-IMT\u2122 treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY\u00ae (sacituzumab govitecan-hziy) in similar heavily pre-treated patients Survival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY\u00ae No Bria-IMT related discontinuations reported to date PHILADELPHIA and VANCOUVER, British Columbia, April 16, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors (CPI), outperforming ADC drugs in hormone receptor positive (HR+) metastatic breast &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-837914","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Median overall survival of 17.3 months in Bria-IMT\u2122 treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY\u00ae (sacituzumab govitecan-hziy) in similar heavily pre-treated patients Survival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY\u00ae No Bria-IMT related discontinuations reported to date PHILADELPHIA and VANCOUVER, British Columbia, April 16, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors (CPI), outperforming ADC drugs in hormone receptor positive (HR+) metastatic breast &hellip; Continue reading &quot;BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T11:34:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzIzNSM2ODY4ODU3IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer\",\"datePublished\":\"2025-04-16T11:34:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\\\/\"},\"wordCount\":941,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMzIzNSM2ODY4ODU3IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\\\/\",\"name\":\"BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMzIzNSM2ODY4ODU3IzIwOTA2NTg=\",\"datePublished\":\"2025-04-16T11:34:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMzIzNSM2ODY4ODU3IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMzIzNSM2ODY4ODU3IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer - Market Newsdesk","og_description":"Median overall survival of 17.3 months in Bria-IMT\u2122 treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY\u00ae (sacituzumab govitecan-hziy) in similar heavily pre-treated patients Survival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY\u00ae No Bria-IMT related discontinuations reported to date PHILADELPHIA and VANCOUVER, British Columbia, April 16, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors (CPI), outperforming ADC drugs in hormone receptor positive (HR+) metastatic breast &hellip; Continue reading \"BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-16T11:34:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzIzNSM2ODY4ODU3IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer","datePublished":"2025-04-16T11:34:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/"},"wordCount":941,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzIzNSM2ODY4ODU3IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/","name":"BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzIzNSM2ODY4ODU3IzIwOTA2NTg=","datePublished":"2025-04-16T11:34:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzIzNSM2ODY4ODU3IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzIzNSM2ODY4ODU3IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=837914"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837914\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=837914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=837914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=837914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}